Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU
source: pixabay.com

Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU

According to a story from mrknewsroom.com, the pharmaceutical companies Merck and AstraZeneca recently announced that the marketing application for the investigational drug olaparib (brand name Lynparza) was recently certified for…

Continue Reading Treatment for BRCA-Mutated Breast Cancer Makes Another Regulatory Hurdle in the EU
Recent Surveys Show What Patients Really Think About Their Standard of Care
Source: Pixabay

Recent Surveys Show What Patients Really Think About Their Standard of Care

An organisation called PatientsLikeMe that helps to represent patients to governments and pharmaceutical companies has published a press release about the results of two recent studies designed to define and…

Continue Reading Recent Surveys Show What Patients Really Think About Their Standard of Care
Phase 3 Trial for Focal Segmental Glomerulosclerosis Drug is About to Begin
source: pixabay.com

Phase 3 Trial for Focal Segmental Glomerulosclerosis Drug is About to Begin

According to an announcement from the pharmaceutical company Retrophin, Inc., the company is starting to move forward with phase 3 trials for its drug candidate sparsentan. The drug is in…

Continue Reading Phase 3 Trial for Focal Segmental Glomerulosclerosis Drug is About to Begin
Close Menu